All In MedTech

FDA Clearance Tracker · P150025

PD-L1 IHC 28-8 pharmDx

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Oct 9, 2015 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Oct 9, 2015

Approved

Time to decision

92 days

Received Jul 9, 2015. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P150025
Device name
PD-L1 IHC 28-8 pharmDx
Applicant location
Santa Clara, CA
Received
Jul 9, 2015
Decided
Oct 9, 2015
Decision
Approved
Supplements
18 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE PD-L1 IHC 28-8 PHARMDX. THIS DEVICE IS INDICATED FOR THE FOLLOWING:1) PD-L1 IHC 28-8 PHARMDX IS A QUALITATIVE IMMUNOHISTO-CHEMICAL ASSAY USING MONOCLONAL RABBIT ANTI-PD-L1, CLONE 28-8 INTENDED FOR USE IN THE DETECTION OF PD-L1 PROTEIN IN FORMALIN-FIXED, PARAFFIN-EMBEDDED (FFPE) NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) TISSUE USING ENVISION FLEX VISUALIZATION SYSTEM ON AUTOSTAINER LINK 48; 2) PD-L1 PROTEIN EXPRESSION IS DEFINED AS THE PERCENTAGE OF TUMOR CELLS EXHIBITING POSITIVE MEMBRANE STAINING AT ANY INTENSITY; AND3) PD-L1 EXPRESSION AS DETECTED BY PD-L1 IHC 28-8 PHARMDX IN NON-SQUAMOUS NSCLC MAY BE ASSOCIATED WITH ENHANCED SURVIVAL FROM OPDIVO (NIVOLUMAB).

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • We could not check whether this was the first decision under its product code.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Agilent Technologies, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.